The largest database of trusted experimental protocols

Osimertinib

Osimertinib: A Targeted Tyrosine Kinase Inhibitor for Non-Small Cell Lung Cancer.
Osimertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for the treatment of metastatic non-small cell lung cancer (NSCLC) with EGFR T790M mutation.
It works by selectively inhibiting mutant EGFR while sparing wild-type EGFR, leading to improved efficacy and reduced adverse effects compared to earlier EGFR TKIs.
Osimertinib has demonstrated superior progression-free survival and overall survival in patients with EGFR-mutant NSCLC, making it a key therapeutic option for this difficult-to-treat cancer.

Most cited protocols related to «Osimertinib»

Eligible patients who were screened at 126 trial centers from August 2014 through September 2015 had histologic or cytologic evidence of locally advanced or metastatic non–small-cell lung cancer and of disease progression after first-line EGFR-TKI therapy. The documented presence of an EGFR mutation and central confirmation of the T790M variant on the cobas EGFR Mutation Test (Roche Molecular Systems) after first-line EGFR-TKI treatment was required. All patients were required to provide a blood sample at screening to test for T790M in plasma circulating tumor DNA (ctDNA) on the cobas EGFR Mutation Test, version 2. Patients with stable, asymptomatic CNS metastases that had not been treated with glucocorticoids for at least 4 weeks before the first dose of a trial drug were eligible for inclusion. Complete eligibility criteria are provided in the trial protocol, available with the full text of this article at NEJM.org.
Publication 2016
BLOOD Circulating Tumor DNA Cytological Techniques Disease Progression EGFR protein, human Eligibility Determination Glucocorticoids Mutation Neoplasm Metastasis Non-Small Cell Lung Carcinoma Patients Pharmaceutical Preparations Plasma
Patients were stratified according to Asian or non-Asian race and were randomly assigned in a 2:1 ratio to receive oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles. Patients without disease progression after four cycles of platinum therapy plus pemetrexed (platinum–pemetrexed group) could continue maintenance pemetrexed according to the approved label.
Treatment continued until disease progression, the development of unacceptable side effects, or a request by either the patient or the physician to discontinue treatment. Patients could receive the trial treatment beyond the point of disease progression (as defined according to the Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1) as long as they were receiving clinical benefit, as judged by the investigator.
According to an amendment to the protocol on December 22, 2014, patients who had been assigned to receive platinum–pemetrexed could cross over to the osimertinib group after objective disease progression, according to investigator assessment and as confirmed by blinded independent central review. All the patients provided written informed consent before screening.
Publication 2016
Asian Persons Body Surface Area Carboplatin Cisplatin Crossing Over, Genetic Disease Progression osimertinib Patients Physicians Platinum

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2020
Four EGFR-TKIs, erlotinib, gefitinib, afatinib and osimertinib were selected as study drugs. Data from the FAERS database were fully anonymized by regulatory authorities. We extracted relevant data from the public release of the FAERS database for the pharmacovigilance disproportionality analysis, which covered the period from January 1, 2004 to March 31, 2018. OpenVigil FDA, a validated pharmacovigilance tool, is adapted to query FAERS data using the openFDA application programming interface (API) for accessing the FDA drug-event database with the additional openFDA drug mapping and duplicate detection functionality49 (link),50 (link), and it is used in many pharmacovigilance studies51 (link),52 (link). OpenVigil operates only on the cleaned FDA data by deleting duplicates or reports with missing data49 (link). After data cleaning by OpenVigil FDA, 6,106,629 reports from 2004 Q1 to 2018 Q1 remained. Among the drugs and AEs in the reports, we only selected reports with drug codes of “Primary Suspect or “Secondary Suspect”.
Full text: Click here
Publication 2020
Afatinib EGFR protein, human Erlotinib Gefitinib osimertinib Pharmaceutical Preparations
Watermelon cells were thawed, expended in dox (2μg/ml) containing media for 96 hours and mCherry positive cells were sorted using a MoFlo Astrios Cell Sorter (Beckman Coulter) and re-plated. Following 96 hours of recovery, the cells were seeded into six-well plates at 300,000 cell per well and were given 24h to attach prior to adding 300nM osimertinib. Dox was continuously added to the media until day 3 of drug treatment. Cells were harvested at day 0 (untreated), 3, 7 and 14 of drug treatment. To obtain cell suspension for single cell profiling, cells were scrapped from the well, washed and resuspended in FACS buffer (0.5% BSA in phosphate-buffered saline), and filtered through a 40μm strainer. To delineate the differences between persister populations, day 14 cells were gated based on mCherry expression. Following sorting, the cells were spun down and approximately 9,000 single cells per sample were loaded to the Chromium Controller (10x Genomics). ScRNA-seq libraries were generated using the 10X Genomics Chromium Single Cell 3’ Kit v2 and the 10x Chromium Controller (10x Genomics) according to the standard v2 protocol. The resulting 3’ scRNA-Seq libraries were pooled together and sequenced with a HiSeq (Illumina, R2 read length 98 base pairs). To increase lineage barcode capture, targeted sequencing of the barcode area was performed using the whole transcriptome amplification product generated as a part the v2 protocol as a PCR template (for primer list see Supplementary Table 4). Targeted libraries were gel purified and sequenced with a MiSeq (Illumina).
Publication 2021
Cells Chromium Oligonucleotide Primers osimertinib Pharmaceutical Preparations Phosphates Population Group Saline Solution Single-Cell RNA-Seq Strains Transcriptome Watermelon

Most recents protocols related to «Osimertinib»

For generation of osimertinib-resistant cell lines and examination of the development of osimertinib resistance, we adopted two different experimental protocols. First, PC9/p53, HCC4006/p53, or H1975/p53 cells (1.2 × 105 per well) were seeded in 12-well plates (Greiner Bio-One) and treated with 1 μM or 600 nM osimertinib for 28 days, and the number of cells per well was counted with a LUNAII automated cell counter (Logos Biosystems, Gyeonggi-do, Republic of Korea) at the indicated times during drug treatment. Second, PC9/p53 cells (1.2 × 105 per well) were seeded in six-well plates (Greiner Bio-One) and exposed to increasing concentrations of osimertinib from 10 nM to 1 μM over a maximum of 30 days, with the osimertinib concentration being increased when the cells had achieved 70% confluence. PC9/p53R248Q, PC9/p53R273H, and PC9/p53R175H cells that acquired resistance to 1 μM osimertinib were defined as osimertinib-resistant cells and studied further.
Full text: Click here
Publication 2024

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2024
All CSF samples were collected after 6 ± 2 h from osimertinib administration and plasma samples were simultaneously collected. The CSF and plasma concentrations of osimertinib were measured using liquid chromatography-tandem mass spectrometry. The CSF penetration rate of osimertinib was estimated based on CSF/plasma concentrations.
Full text: Click here
Publication 2024
Not available on PMC !
All Cerebrospinal fluid (CSF) samples were collected after 6 ± 2 h from osimertinib administration and plasma samples were simultaneously collected. The CSF and plasma concentrations of osimertinib were measured using liquid chromatographytandem mass spectrometry (LC-MS/MS). The CSF penetration rate of osimertinib was estimated based on CSF/plasma concentrations.
Publication 2024
The initial treatment regimen for EGFR-mutated NSCLC involves the administration of third-generation EGFR-TKI Osimertinib, as recommended by the NCCN Clinical Practice Guidelines for NSCLC 2022 V6. A targeted therapy duration of 56 days will be implemented during the study period.
Full text: Click here
Publication 2024

Top products related to «Osimertinib»

Sourced in United States, China, United Kingdom
Osimertinib is a chemical compound used in laboratory research. It is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR). Osimertinib is commonly used in studies related to cancer research and drug development.
Sourced in United States, Germany, China, France
Gefitinib is a tyrosine kinase inhibitor used in laboratory research. It functions by inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase.
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States, China, Germany
Afatinib is a chemical compound used in laboratory research. It functions as a tyrosine kinase inhibitor, targeting specific receptors involved in cellular signaling pathways.
Sourced in United States, China, Germany, Australia
Erlotinib is a laboratory reagent used in research applications. It is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR). Erlotinib is commonly used in cell-based assays and in vitro studies to investigate EGFR signaling pathways.
Sourced in United States, China, Japan
The HCC827 is a cell line derived from a human lung adenocarcinoma. It is commonly used in cancer research and drug discovery studies.
Sourced in United States, Japan, Germany, China, France
The H1975 is a laboratory equipment product offered by American Type Culture Collection. It is a specialized device designed for cell culture-related applications. The core function of the H1975 is to provide a controlled environment for the cultivation and maintenance of various cell lines.
Sourced in United Kingdom, Italy
Osimertinib is a laboratory reagent used in research and development. It functions as a tyrosine kinase inhibitor. Osimertinib is utilized in various scientific studies and experiments, but its intended use should not be extrapolated beyond its core function as a laboratory tool.
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
Sourced in United States, China, Germany, United Kingdom, Japan, France, Canada, Australia, Italy, Switzerland, Belgium, New Zealand, Spain, Israel, Sweden, Denmark, Macao, Brazil, Ireland, India, Austria, Netherlands, Holy See (Vatican City State), Poland, Norway, Cameroon, Hong Kong, Morocco, Singapore, Thailand, Argentina, Taiwan, Province of China, Palestine, State of, Finland, Colombia, United Arab Emirates
RPMI 1640 medium is a commonly used cell culture medium developed at Roswell Park Memorial Institute. It is a balanced salt solution that provides essential nutrients, vitamins, and amino acids to support the growth and maintenance of a variety of cell types in vitro.

More about "Osimertinib"

Osimertinib, also known by its brand name Tagrisso, is a cutting-edge, third-generation tyrosine kinase inhibitor (TKI) that has revolutionized the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.
This targeted therapy selectively inhibits the mutant form of the epidermal growth factor receptor (EGFR) while sparing the wild-type EGFR, leading to improved efficacy and reduced adverse effects compared to earlier EGFR TKIs like Gefitinib, Erlotinib, and Afatinib.
Osimertinib has demonstrated superior progression-free survival and overall survival in patients with EGFR-mutant NSCLC, making it a key therapeutic option for this difficult-to-treat cancer.
In preclinical studies, Osimertinib has shown potent inhibition of EGFR-mutant cell lines, such as HCC827 and H1975, while having minimal impact on wild-type EGFR-expressing cells.
The efficacy of Osimertinib has been evaluated in various clinical trials, where it has consistently outperformed earlier EGFR TKIs.
Researchers have utilized cell culture models, including RPMI 1640 medium and DMSO, to further understand Osimertinib's mechanisms of action and optimize its use in the treatment of EGFR-mutant NSCLC.
As a cutting-edge targeted therapy, Osimertinib has become a game-changer in the management of this challenging disease.
Its selective targeting of mutant EGFR and improved safety profile make it a preferred option for patients with EGFR-driven NSCLC, offering them a better quality of life and improved clinical outcomes.